Catalog No.
Product Name
Application
Product Information
Citations
-
Akt/ROCK Inhibitor
Akt/ROCK-IN-1 is a potent dual inhibitor targeting Akt and ROCK, exhibiting IC50 values of 0.023 nM and 1.47 nM, respectively. This compound demonstrates significant antitumor activity, particularly in neuroblastoma models. It serves as a valuable tool for research into cancer biology and therapeutic development. -
PKCα Inhibitor
Desmethylglycitein (4',6,7-Trihydroxyisoflavone) is an inhibitor of protein kinase C (PKC)α, demonstrating significant anti-cancer and antioxidant activities. It directly binds to CDK1 and CDK2, leading to the suppression of their activity. Additionally, Desmethylglycitein inhibits PI3K in an ATP-competitive manner, affecting downstream signaling pathways and reducing adipogenesis in 3T3-L1 preadipocytes. Its mechanisms make it a valuable tool for research in cancer biology and metabolic disorders. -
PKC Inhibitor
Bisindolylmaleimide X is a potent protein kinase C (PKC) inhibitor that exhibits cell-penetrating properties. It effectively inhibits the proliferation of CD4 T cells in vitro and shows antagonistic activity against cyclin-dependent kinase 2 (CDK2) with an IC50 of 200 nM. Additionally, Bisindolylmaleimide X suppresses eNOS-Ser1177 phosphorylation in human embryonic vein endothelial cells. This compound is valuable for studying mechanisms in the immune system and cardiovascular diseases. -
PKC Activator
1,2-Dimyristoyl-sn-glycerol is a saturated diacylglycerol that acts as a weak second messenger for the activation of Protein Kinase C (PKC). This compound is utilized in research applications to study PKC signaling pathways, which are crucial in various cellular processes including growth, differentiation, and apoptosis. As a PKC activator, it can help elucidate the role of PKC in different biological contexts and disease models. -
PKA Anchoring Inhibitor
st-Ht31 is a membrane-permeable peptide that inhibits protein kinase A (PKA) anchoring. It effectively induces cholesterol and phospholipid efflux and has been shown to completely reverse foam cell formation in macrophages. This compound offers valuable insights into PKA-related signaling pathways and metabolic health research. -
Myo1s/TGF-β Inhibitor
Pentachloropseudilin is a potent reversible allosteric inhibitor targeting Myo1s (class 1 myosins), exhibiting IC50 values ranging from 1 to 5 μM for mammalian class-1 myosins, while displaying greater than 90 μM for class-2 and class-5 myosins. Additionally, it effectively inhibits transforming growth factor-β (TGF-β) signaling, with an IC50 of 0.1 to 0.2 μM. This compound is valuable for research in cellular signaling pathways and myosin function, contributing to studies in cell motility and tissue remodeling. -
PKC Inhibitor
PKC-iota inhibitor 1 is an inhibitor of protein kinase C-iota (PKC-ι) with an IC50 value of 0.34 μM. This compound demonstrates significant biological activity relevant to cancer research, making it a valuable tool for investigating the role of PKC-ι in tumorigenesis and signal transduction pathways. It is suitable for studies focused on cancer biology and therapeutic interventions targeting PKC-ι. -
PKC Inhibitor
DL-erythro-Dihydrosphingosine is a sphingosine-derived protein kinase C (PKC) inhibitor that functions by directly inhibiting phospholipase A2 (PLA2) activity. This compound also attenuates the function of Bcl-2, a protein that plays a crucial role in regulating apoptosis. Additionally, DL-erythro-Dihydrosphingosine inhibits matrix metalloproteinases (MMPs), which are involved in various cellular processes. Its unique biological activity makes it valuable for research in cancer and inflammatory disease models. -
PKC/HCMV Inhibitor
Bisindolylmaleimide IV is a selective inhibitor of protein kinase C (PKC), exhibiting IC50 values between 0.1 and 0.55 μM. It also demonstrates inhibition of protein kinase A (PKA) with IC50 ranging from 3.1 to 11.8 μM. In addition to its kinase inhibitory properties, Bisindolylmaleimide IV effectively inhibits human cytomegalovirus (HCMV) replication in cell culture, displaying an IC50 of 0.2 μM. This reagent is valuable for research applications focused on signal transduction and viral pathogenesis. -
PKC Inhibitor
Sangivamycin is a nucleoside analog that serves as a potent inhibitor of protein kinase C (PKC) with a Ki value of 10 μM. This compound exhibits significant antiproliferative activity against a diverse range of human cancers, making it a valuable tool for cancer research and therapeutic studies focused on PKC modulation. Its targeted mechanism of action positions Sangivamycin as a promising candidate for further exploration in cancer treatment. -
Anti-CD73/TGF-β Antibody
Dalutrafusp alfa is a bifunctional antibody that targets CD73 and TGF-β, key components involved in the immunosuppressive pathway. This compound modulates immune responses by inhibiting adenosine production and blocking TGF-β signaling. It is primarily utilized in research focused on tumor immunology and the modulation of immune checkpoints. Its unique mechanism allows for exploration in various therapeutic applications, particularly in cancer treatment and autoimmune diseases. -
p32-kinase activator
D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator. -
PKC inhibitor
Ruboxistaurin (LY333531) is a potent, selective inhibitor of Protein Kinase C isozymes, PKC β I(IC50=4.7 nM) and PKC β II (IC50=5.9 nM). -
PKC inhibitor
PKC 412 is a broad spectrum protein kinase inhibitor. Inhibits conventional PKC isoforms α/β/γ, PDFRβ, VEGFR2, Syk, Flk-1, Flt3, Cdk1/B, PKA, c-Kit, c-Fgr, c-Src, VEGFR1 and EGFR. Displays potent antitumor activity. -
BMP receptor inhibitor
LDN-212854 is an ALK2-Biased BMP Type I Receptor Kinase Inhibitor. -
δ-protein kinase C (δPKC) inhibitor
Delcasertib (KAI-9803) is a potent and selective δ-protein kinase C (δPKC) inhibitor. -
Smad inhibitor
Kartogenin potently induces differentiation of human mesenchymal stem cells into chondrocytes -
PKC inhibitor
GF 109203X is a potent and selective inhibitor of protein kinase C, selective for the α and β1 isoforms (IC50 values are 0.0084, 0.0180, 0.210, 0.132, and 5.8 μM for α, β1, δ, ε and ζ isoforms respectively). Selective over MLCK, PKG and PKA (IC50 values are 0.6, 4.6, and 33 μM respectively). Potent antagonist at the 5-HT3 receptor (Ki = 29.5 nM). -
PKC inhibitor
Sotrastaurin is a protein kinase C inhibitor for the prevention of transplant rejection and treatment of psoriasis. -
ROCK inhibitor
Y-33075 dihydrochloride is a selective ROCK inhibitor with an IC50 of 3.6 nM. -
PKA, PKG, Casein Kinase I and II inhibitor
A-3 Hydrochloride is an inhibitor of PKA (cAMP-dependent protein kinase, Ki=4.3μM) and cGMP-dependent protein kinase, Ki=3.8μM, PKC (protein kinase C, Ki=47μM), casein kinase I and II, and MLCK (myosin light chain kinase) ( Ki=7.4μM). -
MAPKAP-K2 (MK-2) inhibitor
MK-2 Inhibitor III (compound 16) is an orally active, selective, and ATP-competitive MAPKAP-K2 (MK-2) inhibitor with an IC50 of 0.85 nM. -
ROCK inhibitor
Glycyl-H 1152 2HCl is a selective and potent ROCK inhibitor (IC50 values are 0.0118, 2.35, 2.57, 3.26, > 10 and >10 uM for ROCKII, Aurora A, CAMKII, PKG, PKA and PKC respectively.) -
PKC activator
Prostratin is a protein kinase C activator found in the bark of the mamala tree of Samoa, Homalanthus nutans. -
ROCK Inhibitor
HA-1077 inhibits vascular smooth muscle contraction by acting as an intracellular Ca2+ antagonist. - Valrubicin is a semisynthetic derivative of the antineoplastic anthracycline antibiotic doxorubicin.
-
PKs inhibitor
HA-100 is an isoquinoline compound with an added piperazinylsulfonyl group that acts as an inhibitor of protein kinases (PKs), including PKA, PKC, and PKG (IC50 = 8, 12, and 4 μM, respectively). -
protein kinase A activator
8-Bromo-cAMP is a cell perbeable cyclic AMP (cAMP) analog and a PKA activator. -
ROCK inhibitor
SAR407899 is a potent and selective Rho kinase inhibitor with promising antihypertensive activity. -
PKA-selective activator
6-Bnz-cAMP is a PKA-selective activator. It regulates the PKA dependent signaling pathways. -
reversible PKA inhibitor
Rp-cAMPS is a cell-permeable and reversible inhibitor of PKA (protein kinase A) (Ki = 11 uM). Rp-cAMPS is resistant to hydrolysis by phosphodiesterases and is noncompetitive with respect to ATP. -
PKG/PKA inhibitor
cGMP Dependent Kinase Inhibitor Peptid is a specific cGKI (cyclic GMP-dependent protein kinase) inhibitor. Data indicates that it does not block cyclic GMP-dependent protein kinase phosphorylation of intact histones and has been used to study Plasmodium falciparum. -
ALK2 inhibitor
LDN-214117 is a selective and potent ALK2 inhibitor. LDN-214117 inhibited ALK2 most, with a biochemical IC50 of 24 nM.
